Welcome to our dedicated page for ALNYLAM PHARMACEUTICALS SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals Chief Executive Officer Yvonne Greenstreet reported automatic tax-related stock sales. On March 4, 2026, she sold a total of 2,933 shares of Alnylam common stock in a series of open-market transactions, at weighted average prices ranging from about $318 to $326 per share.
According to the disclosure, these sales were executed by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding tied to vesting restricted stock units. After these sales, Greenstreet directly owned 95,695 shares, and also held 407 shares indirectly through a managed account related to the company’s 401(k) matching program.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales. Reported prices for these transactions include $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share.
According to a footnote, these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations upon the vesting of restricted stock units. After these sales, Poulton directly owned 62,028 shares and indirectly held 57 shares of ALNY common stock through a managed account.
ALNYLAM PHARMACEUTICALS, INC. executive officer Tanguler Tolga reported automatic sales of common stock tied to equity compensation. On March 4, 2026, a total of 2,309 shares of common stock were sold in multiple open‑market transactions.
According to a footnote, these shares were sold by the company on the reporting person’s behalf under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding upon vesting of restricted stock units. After these sales, the reporting person directly held 34,297 common shares.
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock. On March 4–5, 2026, he sold a total of 1,291 shares of common stock in multiple transactions at prices generally in the low $320 range.
Footnotes state that some shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding on vested restricted stock units, and that the transactions were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025. After these sales, Fitzgerald directly owns 20,569 common shares and indirectly holds 537 shares through a managed account associated with the company’s 401(k) matching program.
ALNY reports a Rule 144 notice to sell 658 RSUs slated on 03/03/2026. The filing also lists three reported sales by Kevin Fitzgerald: 01/13/2026 (2290 shares, $848,062.57), 02/17/2026 (2041 shares, $677,531.58), and 03/03/2026 (1652 shares, $528,187.85).
ALNY affiliate filed a Form 144 disclosing a proposed sale of 2,404 common shares arising from restricted stock units dated 03/03/2026. The filing also reports prior sales by Pushkal Garg of 4,627 shares on 02/27/2026 for $1,533,106.94 and 1,775 shares on 03/03/2026 for $567,544.89.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported a mix of equity awards and stock sales. He received a stock option for 10,480 shares and 4,769 restricted stock units, both granted on March 2, 2026. The RSUs vest in three equal annual installments over three years, and the option vests over four years with 25% after one year and the balance quarterly thereafter, in each case subject to continued service. On the same date, he sold 2,206 shares of common stock in a series of open‑market transactions at weighted average prices in the low‑ to mid‑$320s per share, pursuant to a mandatory sell‑to‑cover provision to satisfy minimum tax withholding. Following these transactions, he directly held 64,273 common shares and indirectly held 57 shares through a managed account.
ALNY’s EVP and Chief R&D officer Pushkal Garg reported a mix of stock sales and equity awards. On March 2, 2026, he received a stock option for 10,480 shares and 4,769 restricted stock units under Alnylam’s 2018 Stock Incentive Plan, with both awards vesting over time based on continued service.
On March 2 and 3, 2026, he conducted open-market sales totaling 3,492 common shares at prices generally in the $316–$332 range, some under a Rule 10b5-1 trading plan and some automatically sold to cover tax withholding on the equity awards. Footnotes also show 431 shares held via a 401(k) managed account and 250 shares held in a trust for which he disclaims beneficial ownership.
ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported a mix of stock sales and equity awards. On March 2, 2026, he received a grant of 8,105 stock options and 3,688 shares of common stock represented by restricted stock units that vest in thirds over three years, subject to continued service. The stock options vest over four years, with 25% after one year and the balance in quarterly installments.
Across March 2–3, 2026, he executed open‑market sales totaling 3,250 common shares, some under a mandatory sell‑to‑cover tax provision and under a Rule 10b5‑1 trading plan adopted on August 14, 2025. After these transactions, he directly held 21,860 common shares, 8,105 options, and indirectly held 537 shares through a managed account.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief commercial officer Tolga Tanguler reported a mix of equity awards and related share sales. On March 2, 2026, he received stock options for 10,480 shares and a grant of 4,769 shares of common stock represented by restricted stock units that vest over three years.
On the same date, a total of 1,598 shares of common stock were sold in multiple open-market transactions at reported weighted-average prices in the low $320s to low $330s per share. According to the disclosure, these sales were automatically executed under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations. Following these transactions, Tanguler directly owned 36,606 shares of Alnylam common stock.